DelveInsight’s Pancreatic Cancer Market Insights report includes a comprehensive understanding of current treatment practices, pancreatic cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.
Key Takeaways from the Pancreatic Cancer Market Report
- According to DelveInsight estimates, the pancreatic cancer market size in the 7MM was approximately USD 1,649 million in 2021.
- As per our analysis, the total incident cases of pancreatic cancer were approx 175K in the 7MM in 2021.
- Key pancreatic cancer companies such as AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, Bristol Myers Squibb, BioLineRx, Alligator Bioscience, Bellicum Pharmaceuticals, OSE Immunotherapeutics, Actuate Therapeutics, FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, Merus, Mirati Therapeutics, Rexahn Pharmaceuticals, Ocuphire Pharma, Processa Pharmaceuticals, ImmunityBio, Berg, Panbela Therapeutics, GlaxoSmithKline, Eleison Pharmaceuticals, Molecular Templates, Lokon Pharma AB, Cantargia AB, and others are developing novel pancreatic cancer drugs that can be available in the pancreatic cancer market in the upcoming years.
- Promising pancreatic cancer therapies in the pipeline include Motixafortide, Mitazalimab, BPX-601, Tedopi (OSE2101), AZD5305, Elraglusib (9 ING 41), NT-I7 (Efineptakin Alfa), Olaptesed pegol (NOX-A12), siG12D LODER, Sotorasib (LUMAKRAS/AMG 510), NGM120, Zenocutuzumab (Zeno, MCLA-128), Adagrasib (MRTX849), RX-3117, Anktiva (N-803), BPM31510 (ubidecarenone), Zejula (niraparib), Glufosfamide, LOAd703 (delolimogene mupadenorepvec), Pamrevlumab, GVAX Pancreatic Tumor Vaccine, and others.
Discover more about therapies set to grab major pancreatic cancer market share @ Pancreatic Cancer Research
Pancreatic Cancer Overview
Pancreatic cancer develops in the pancreas tissues, an organ in the abdomen located behind the bottom portion of the stomach. The pancreas secretes hormones that help control blood sugar and enzymes that aid digestion. Pancreatic cancer is a condition in which malignant (cancer) cells develop in pancreatic tissues. The pancreas can develop tumors in various ways, including malignant and noncancerous tumors. However, the precise causes of pancreatic cancer are unknown. Individuals diagnosed with pancreatic cancer before the tumor develops or spreads have an average life expectancy of 3 to 3.5 years.
Jaundice, dark urine, weight loss, loss of appetite, fatigue, and other symptoms of pancreatic cancer may occur. The symptoms of pancreatic cancer are frequently confused with those of other disorders, such as irritable bowel syndrome. The severity of cancer determines the treatment options for pancreatic cancer. Surgery, chemotherapy, radiation therapy, targeted therapy, or a combination of these may be options.
Learn more about the diseases and pancreatic cancer diet @ Pancreatic Cancer Tests
Pancreatic Cancer Epidemiology Segmentation
The pancreatic cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Incident Cases of Pancreatic Cancer
- Molecular Alteration-specific Incident Cases of Pancreatic Cancer
- Stage-specific Incident Cases of Pancreatic Cancer
Download the report to understand which factors are driving pancreatic cancer epidemiology trends @ Pancreatic Cancer Epidemiological Insights
Pancreatic Cancer Treatment Market
Patients with the localized or regional disease are more likely to benefit from surgical treatment. Aside from surgery, the most common pharmaceutical pancreatic cancer treatment option is chemotherapy. In all cases, it is preferred for pancreatic cancer patients. In first-line therapy, gemcitabine-based chemotherapeutic regimens are preferred over 5-FU-based and other regimens due to fewer side effects associated with gemcitabine compared to 5-FU-based treatment options.
Individuals who meet certain criteria and have received first-line FOLFIRINOX can receive gemcitabine + nab-paclitaxel as second-line therapy. For patients with a slightly lower performance status (ECOG 2), those with medical comorbidities, or the elderly, monotherapy with GEM or 5-FU is an option in the second-line scenario.
To know more about pancreatic cancer treatment options, visit @ Pancreatic Cancer Prevention
Pancreatic Cancer Pipeline Therapies and Key Companies
- Motixafortide (BL-8040): BioLineRx/Merck Sharp & Dohme
- Mitazalimab (ADC-1013): Alligator Bioscience
- BPX-601: Bellicum Pharmaceuticals
- Tedopi (OSE2101): OSE Immunotherapeutics
- AZD5305: Astra Zeneca
- Elraglusib (9 ING 41): Actuate Therapeutics
- Pamrevlumab (FG-3019): FibroGen
- NT-I7 (Efineptakin Alfa): NeoImmuneTech
- Olaptesed pegol (NOX-A12): NOXXON Pharma
- siG12D LODER: Silenseed Ltd
- Sotorasib (LUMAKRAS/AMG 510): Amgen
- NGM120: NGM Biopharmaceuticals
- Zenocutuzumab (Zeno, MCLA-128): Merus
- Adagrasib (MRTX849): Mirati Therapeutics
- RX-3117: Rexahn Pharmaceuticals/Ocuphire Pharma/Processa Pharmaceuticals
- Anktiva (N-803): ImmunityBio
- BPM31510 (ubidecarenone): Berg
- SBP-101: Panbela Therapeutics
- Zejula (niraparib): GlaxoSmithKline/Bristol Myers Squibb
- Glufosfamide: Eleison Pharmaceuticals/Molecular Templates
- LOAd703 (delolimogene mupadenorepvec): Lokon Pharma AB
- CAN04 (Nadunolimab): Cantargia AB
- GVAX Pancreatic Tumor Vaccine: Bristol-Myers Squibb
Learn more about the pancreatic cancer therapies in clinical trials @ New Treatment for Pancreatic Cancer
Pancreatic Cancer Market Dynamics
As the number of cases of pancreatic cancer rises, so does the size of the pancreatic cancer market. Furthermore, survival in pancreatic cancer patients is improving all the time, implying that a better understanding of tumor pathobiology will lead to better therapies and outcomes in the pancreatic cancer market. In addition, due to a lack of randomized neoadjuvant trials, research into the use of newer and more aggressive systemic regimens in the neoadjuvant setting to treat PDAC could potentially improve outcomes in the pancreatic cancer market.
Several factors, however, limit the growth of the pancreatic cancer market. PDAC is a difficult disease with significant intra-tumoral heterogeneity and a thick, desmoplastic stroma that may limit drug delivery to the tumor. Furthermore, it foreshadows an extremely complex intercellular signaling interplay, making in vitro disease research difficult. PDAC is one of the most chemo-resistant types of cancer due to the genetic mutation diversity and dense connective tissue that forms the pancreas.
Furthermore, the introduction of generics into the pancreatic cancer market, the expiration of patent protection for certain medications, rising healthcare costs, and patient nihilism are all major threats to the pancreatic cancer market.
Scope of the Pancreatic Cancer Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Pancreatic Cancer Companies: AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, Bristol Myers Squibb, BioLineRx, Alligator Bioscience, Bellicum Pharmaceuticals, OSE Immunotherapeutics, Actuate Therapeutics, FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, Merus, Mirati Therapeutics, Rexahn Pharmaceuticals, Ocuphire Pharma, Processa Pharmaceuticals, ImmunityBio, Berg, Panbela Therapeutics, GlaxoSmithKline, Eleison Pharmaceuticals, Molecular Templates, Lokon Pharma AB, Cantargia AB, and others
- Key Pancreatic Cancer Therapies: Motixafortide, Mitazalimab, BPX-601, Tedopi (OSE2101), AZD5305, Elraglusib (9 ING 41), NT-I7 (Efineptakin Alfa), Olaptesed pegol (NOX-A12), siG12D LODER, Sotorasib (LUMAKRAS/AMG 510), NGM120, Zenocutuzumab (Zeno, MCLA-128), Adagrasib (MRTX849), RX-3117, Anktiva (N-803), BPM31510 (ubidecarenone), Zejula (niraparib), Glufosfamide, LOAd703 (delolimogene mupadenorepvec), GVAX Pancreatic Tumor Vaccine, and others
- Therapeutic Assessment: Pancreatic Cancer current marketed and emerging therapies
- Pancreatic Cancer Market Dynamics: Pancreatic Cancer market drivers and barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Pancreatic Cancer Market Access and Reimbursement
Discover more about pancreatic cancer drugs in development @ Pancreatic Cancer Clinical Trials
Table of Contents
| 1. | Pancreatic Cancer Market Key Insights |
| 2. | Pancreatic Cancer Market Report Introduction |
| 3. | Pancreatic Cancer Market Overview at a Glance |
| 4. | Pancreatic Cancer Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | Pancreatic Cancer Treatment and Management |
| 7. | Pancreatic Cancer Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | Pancreatic Cancer Marketed Drugs |
| 10. | Pancreatic Cancer Emerging Drugs |
| 11. | Seven Major Pancreatic Cancer Market Analysis |
| 12. | Pancreatic Cancer Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Pancreatic Cancer Market Drivers |
| 16. | Pancreatic Cancer Market Barriers |
| 17. | Unmet Needs |
| 18. | SWOT Analysis |
| 19. | Appendix |
| 20. | DelveInsight Capabilities |
| 21. | Disclaimer |
| 22. | About DelveInsight |
Get in touch with our Business executive @ Healthcare Due Diligence Services
Related Reports
Pancreatic Cancer Epidemiology
Pancreatic Cancer Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical, and forecasted Pancreatic Cancer epidemiology in the 7MM.
Pancreatic Cancer Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key pancreatic cancer companies, including FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, among others.
Advanced Pancreatic Cancer Market
Advanced Pancreatic Cancer Market Insight, Epidemiology, and Market Forecast, 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key advanced pancreatic cancer companies, including AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, among others.
Advanced Pancreatic Cancer Pipeline
Advanced Pancreatic Cancer Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key advanced pancreatic cancer companies, including FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, among others.
Metastatic Pancreatic Cancer Market
Metastatic Pancreatic Cancer Market Insight, Epidemiology, and Market Forecast, 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key metastatic pancreatic cancer companies, including Takeda Oncology, Salspera, Eli Lilly and Company, among others.
Metastatic Pancreatic Cancer Pipeline
Metastatic Pancreatic Cancer Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key metastatic pancreatic cancer companies, including Takeda Oncology, Salspera, Eli Lilly and Company, among others.
Other Trending Reports
Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Global Kinase Inhibitor in Autoimmune Diseases Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market |Spirometers Market | Hemodynamic Monitoring Systems Market | Deep Brain Stimulation Devices Market | Genital Herpes Market | Guillain-Barre Syndrome (GBS) Market | Hot Flashes Market | Human Immunodeficiency Virus Type-1 (HIV-1) Market | Hypertrophic Scar Market | Sinus Dilation Devices Market | Artificial Cornea and Corneal Implant Market |Peripheral Neuritis Market | Peripheral Vascular Devices Market | Diphtheria Market | Glioma Market | Fallopian Tube Cancer Market | Implantable Cardioverter Defibrillators (ICDs) Market | Smart Inhalers Market | Hemophilia A Market | Hemostasis Market | Peptic Ulcers Market
Related Healthcare Blogs
Related Cases Studies
Related Conferences
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187